Hangzhou Sumgen Biotech Co., Ltd. (hereinafter “Sumgen”) has formally announced the completing of a 220 million RMB series B funding led by Addor Capital, co-led by Cowin Capital and Sinowisdom, and jointly participated by BOCOM International, Haoshuo Investment, and Dynamic Balance Capital. This round of funding is primarily used for the R&D and industrialization of Sumgen’s innovative drugs. StartPointAdvisors served as the exclusive financial consultant for this funding round.
Copyright Rm. 301, F3, Building C, Block 2, No. 688, Bin'an Road, Changhe Zhejiang ICP Filing No. 18039044
